Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
subcutaneous drug delivery
Pharma
Sanofi's subQ version of Sarclisa measures up to its IV version
A phase 3 trial of Sanofi's subcutaneous version of Sarclisa has met its primary co-endpoints, showing non-inferiority to intravenous Sarclisa.
Kevin Dunleavy
Jan 9, 2025 11:14am
FDA approves BMS' subcutaneous Opdivo with some limitations
Jan 2, 2025 9:15am
Novo at last scores US green light for daily hemophilia med
Dec 23, 2024 10:33am
ASH: Roche's subQ Lunsumio matches IV version in lymphoma
Dec 9, 2024 3:16pm
Merck moves a step closer with subcutaneous version of Keytruda
Nov 19, 2024 10:20am
Merck and BioNTech's I-O bispecific buys—Fierce Pharma Asia
Nov 15, 2024 8:20am